In short
A groundbreaking clinical trial is underway to evaluate the effectiveness of a personalized peptide vaccine, including Pervi-Neo, for children and young adults with metastatic fusion-driven sarcomas. This phase I/II trial aims to assess the vaccine's ability to induce T-cell responses in patients who have undergone standard treatment for Ewing sarcoma, alveolar rhabdomyosarcoma, or synovial sarcoma. The study focuses on patients in first or second complete remission or partial response, offering hope for improved outcomes in these aggressive cancers.
At a glance
- Trial Type
- Phase I/II
- Target Population
- Children and young adults (2-40 years) with metastatic fusion-driven sarcomas
- Conditions
- Ewing sarcoma, alveolar rhabdomyosarcoma, synovial sarcoma
- Treatment
- Personalized peptide vaccine (IPX vaccine) including Pervi-Neo
- Primary Objective
- Assess vaccine-induced T-cell response
- Secondary Objectives
- Evaluate feasibility, safety, and early efficacy data
- Primary Endpoint
- T-cell response without unacceptable toxicity
- Key Secondary Endpoints
- T-cell responses, Event-free survival, Overall survival, Quality of life
- Dosage
- Max daily dose: 0.3 mg, Max total dose: 0.9 mg
- Treatment Duration
- Up to 113 days
What is PERVI-NEO?
PERVI-NEO is part of an innovative personalized peptide vaccine called IPX vaccine, which is currently being studied for the treatment of certain types of metastatic sarcomas in children and young adults. This vaccine is designed to be tailored to each patient's specific cancer characteristics, making it a form of personalized medicine.
The IPX vaccine contains three main components:
- PERVI-FUS: A peptide targeting fusion proteins specific to certain sarcomas
- PERVI-NEO: A peptide targeting patient-specific cancer mutations
- 11902A: Another component of the vaccine formulation
These components are combined in an emulsion for injection, which means they are mixed into a liquid form that can be injected into the patient.
Target Conditions
The PERVI-NEO vaccine is being studied for use in patients with specific types of metastatic sarcomas, which are cancers that develop in soft tissues or bones and have spread to other parts of the body. The targeted sarcomas are known as "fusion-driven" sarcomas, including:
- Ewing sarcoma: A rare cancer that typically affects bones or soft tissues around bones
- Alveolar rhabdomyosarcoma: A type of soft tissue cancer that develops in muscle tissue
- Synovial sarcoma: A rare cancer that can occur in various locations in the body, often near joints
The term "fusion-driven" refers to these cancers being caused by specific genetic alterations where parts of two different genes fuse together, creating an abnormal protein that drives cancer growth.
How PERVI-NEO Works
PERVI-NEO is designed to stimulate the patient's immune system to recognize and attack cancer cells. Here's how it works:
- Scientists analyze the patient's cancer cells to identify specific genetic mutations and fusion proteins.
- Based on this analysis, they create personalized peptides (small protein fragments) that match the patient's cancer characteristics.
- These peptides are then used to create the vaccine, which includes PERVI-FUS (targeting fusion proteins) and PERVI-NEO (targeting patient-specific mutations).
- When injected, the vaccine is designed to "train" the patient's immune system, particularly T cells (a type of white blood cell), to recognize and attack cancer cells displaying these specific peptides.
Clinical Trial Details
PERVI-NEO is currently being studied in a Phase I/II clinical trial. Here are some key details about the study:
- Trial objective: To assess the ability of the individualized fusion-peptide and neopeptide vaccination to induce a T-cell response in patients
- Secondary objectives: To evaluate the feasibility, safety, and tolerability of the vaccine, as well as gather early efficacy data
- Patient group: Children and young adults (ages 2-40) with metastatic fusion-driven sarcomas who have completed standard treatment and are in complete remission or partial response
- Dosage: The maximum daily dose is 0.3 mg, with a maximum total dose of 0.9 mg over the treatment period
- Treatment duration: Up to 113 days
Eligibility Criteria
To participate in the clinical trial, patients must meet specific criteria. Some key inclusion criteria include:
- Confirmed metastatic fusion-driven rhabdomyosarcoma, Ewing sarcoma, or synovial sarcoma
- Complete remission or partial response after standard therapy
- Availability of genetic sequencing data for the patient's cancer
- Successful design and production of the patient-specific vaccine
There are also several exclusion criteria, such as certain medical conditions, ongoing infections, or use of medications that might interfere with the vaccine's effectiveness.
Potential Benefits and Risks
As PERVI-NEO is still in clinical trials, its full benefits and risks are not yet known. However, potential benefits and considerations include:
- Potential benefits:
- Personalized treatment approach
- Potential to stimulate the immune system against cancer cells
- May help prevent cancer recurrence in high-risk patients
- Considerations and potential risks:
- As with any medical treatment, there may be side effects or risks
- The effectiveness of the treatment is still being studied
- The treatment requires genetic analysis and personalized vaccine production, which may take time
It's important to note that PERVI-NEO is still an experimental treatment. Patients and families considering participation in the clinical trial should discuss the potential benefits and risks thoroughly with their healthcare team.